Back

Development and Internal Validation of the AB-IPI using Bootstrapping: A Clinicopathological Prognostic Score Integrating Host Fitness and Tumor Biology in Diffuse Large B-Cell Lymphoma

2026-02-19 hematology Title + abstract only
View on medRxiv
Show abstract

ObjectivesThe therapeutic efficacy of rituximab has reduced the discriminatory power of the International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL), particularly within intermediate-risk categories. To address this "risk dilution," we aimed to develop and internally validate the AB-IPI (Albumin-BCL2 Refined Prognostic Index) using a hypothesis-driven approach that integrates tumor burden, host fitness, and tumor biology. MethodsThis multi-center retrospective study analyze...

Predicted journal destinations